Angeles Alvarez Secord, MD, MHSc
Articles
Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer
Angeles Alvarez Secord, MD, MHSc ;Dana M. Chase, MD, FACOG;Bhavana Pothuri, MD;Premal H. Thaker, MD, MS;Thomas C. Krivak, MD
September 30th 2024Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.
Read More
Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
Angeles Alvarez Secord, MD, MHSc ;Dana M. Chase, MD, FACOG;Bhavana Pothuri, MD;Premal H. Thaker, MD, MS;Thomas C. Krivak, MD
September 30th 2024Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.
Read More
Latest Updated Articles
Published: May 27th 2024 | Updated: September 13th 2024
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: September 26th 2024 | Updated: October 1st 2024
State of the Science Summit - GU Cancers: Chaired by Mehmet Asim Bilen, MD, and Jacqueline T. Brown, MD
